Moody Lynn & Lieberson LLC Sells 745 Shares of Danaher Co. (DHR)

Moody Lynn & Lieberson LLC lowered its stake in Danaher Co. (NYSE:DHR) by 13.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,966 shares of the conglomerate’s stock after selling 745 shares during the quarter. Moody Lynn & Lieberson LLC’s holdings in Danaher were worth $505,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. ETRADE Capital Management LLC raised its position in shares of Danaher by 5.1% during the 2nd quarter. ETRADE Capital Management LLC now owns 19,075 shares of the conglomerate’s stock valued at $1,610,000 after buying an additional 917 shares in the last quarter. Roundview Capital LLC raised its position in shares of Danaher by 2.0% during the 2nd quarter. Roundview Capital LLC now owns 25,674 shares of the conglomerate’s stock valued at $2,167,000 after buying an additional 502 shares in the last quarter. Honeywell International Inc. raised its position in shares of Danaher by 113.4% during the 3rd quarter. Honeywell International Inc. now owns 640,100 shares of the conglomerate’s stock valued at $54,908,000 after buying an additional 340,100 shares in the last quarter. Veritable L.P. raised its position in Danaher by 28.2% in the 2nd quarter. Veritable L.P. now owns 40,486 shares of the conglomerate’s stock worth $3,417,000 after purchasing an additional 8,912 shares during the period. Finally, Wealthfront Inc. raised its position in Danaher by 10.2% in the 2nd quarter. Wealthfront Inc. now owns 14,574 shares of the conglomerate’s stock worth $1,230,000 after purchasing an additional 1,348 shares during the period. Institutional investors and hedge funds own 76.19% of the company’s stock.

A number of analysts recently weighed in on the stock. Cowen reissued a “buy” rating and issued a $110.00 price objective on shares of Danaher in a research report on Tuesday, January 30th. Credit Suisse Group upped their target price on shares of Danaher from $99.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Royal Bank of Canada restated a “hold” rating and issued a $98.00 target price on shares of Danaher in a research note on Wednesday, January 31st. Morgan Stanley upped their target price on shares of Danaher from $103.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 31st. Finally, Stifel Nicolaus increased their price objective on shares of Danaher from $110.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. Danaher has a consensus rating of “Buy” and an average target price of $100.13.

Danaher Co. (DHR) traded up $2.30 during midday trading on Friday, hitting $94.46. 3,684,046 shares of the company’s stock were exchanged, compared to its average volume of 2,870,000. The stock has a market capitalization of $65,710.00, a PE ratio of 26.99, a P/E/G ratio of 1.99 and a beta of 1.04. Danaher Co. has a fifty-two week low of $78.97 and a fifty-two week high of $104.82. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.39.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.03. Danaher had a net margin of 13.60% and a return on equity of 11.36%. The business had revenue of $5.09 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter last year, the company posted $1.05 earnings per share. The business’s quarterly revenue was up 10.9% on a year-over-year basis. sell-side analysts forecast that Danaher Co. will post 4.37 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, January 26th. Investors of record on Friday, December 29th were issued a dividend of $0.14 per share. The ex-dividend date was Thursday, December 28th. This represents a $0.56 annualized dividend and a dividend yield of 0.59%. Danaher’s dividend payout ratio (DPR) is presently 16.00%.

In related news, SVP Daniel Raskas sold 37,870 shares of the firm’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Angela S. Lalor sold 42,988 shares of the firm’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $102.29, for a total transaction of $4,397,242.52. Following the transaction, the senior vice president now directly owns 82,008 shares of the company’s stock, valued at approximately $8,388,598.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 274,913 shares of company stock valued at $27,729,293. 12.20% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Moody Lynn & Lieberson LLC Sells 745 Shares of Danaher Co. (DHR)” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://stocknewstimes.com/2018/02/11/moody-lynn-lieberson-llc-reduces-stake-in-danaher-co-dhr.html.

Danaher Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply